CN108025023A - 用于干细胞移植的方法 - Google Patents

用于干细胞移植的方法 Download PDF

Info

Publication number
CN108025023A
CN108025023A CN201680053465.0A CN201680053465A CN108025023A CN 108025023 A CN108025023 A CN 108025023A CN 201680053465 A CN201680053465 A CN 201680053465A CN 108025023 A CN108025023 A CN 108025023A
Authority
CN
China
Prior art keywords
day
cells
cell
regimen
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680053465.0A
Other languages
English (en)
Chinese (zh)
Inventor
劳伦斯·S·兰姆
峯岸伸
艾曼·萨德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Priority to CN202210691597.3A priority Critical patent/CN115137752A/zh
Publication of CN108025023A publication Critical patent/CN108025023A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201680053465.0A 2015-08-25 2016-08-25 用于干细胞移植的方法 Pending CN108025023A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210691597.3A CN115137752A (zh) 2015-08-25 2016-08-25 用于干细胞移植的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209721P 2015-08-25 2015-08-25
US62/209,721 2015-08-25
PCT/US2016/048738 WO2017035375A1 (en) 2015-08-25 2016-08-25 Methods for stem cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210691597.3A Division CN115137752A (zh) 2015-08-25 2016-08-25 用于干细胞移植的方法

Publications (1)

Publication Number Publication Date
CN108025023A true CN108025023A (zh) 2018-05-11

Family

ID=58101080

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680053465.0A Pending CN108025023A (zh) 2015-08-25 2016-08-25 用于干细胞移植的方法
CN202210691597.3A Pending CN115137752A (zh) 2015-08-25 2016-08-25 用于干细胞移植的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210691597.3A Pending CN115137752A (zh) 2015-08-25 2016-08-25 用于干细胞移植的方法

Country Status (10)

Country Link
US (2) US20190183930A1 (https=)
EP (2) EP4458953A3 (https=)
JP (2) JP7105188B2 (https=)
KR (2) KR20180041229A (https=)
CN (2) CN108025023A (https=)
AU (2) AU2016312610B2 (https=)
CA (1) CA2996522A1 (https=)
ES (1) ES2984387T3 (https=)
IL (1) IL257678B2 (https=)
WO (1) WO2017035375A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137752A (zh) * 2015-08-25 2022-10-04 Uab研究基金会 用于干细胞移植的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017234010B2 (en) * 2016-03-14 2024-06-13 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
US11421005B2 (en) 2016-12-09 2022-08-23 The Uab Research Foundation Chimeric chlorotoxin receptors
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
BR112019026498A2 (pt) * 2017-06-14 2020-07-14 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd25
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
CA3114292A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
KR20200145328A (ko) 2019-06-21 2020-12-30 안혜빈 자동 물분사 칠판지우개
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞媒介性自己免疫疾患の治療におけるベト細胞の使用
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2025122271A1 (en) * 2023-12-08 2025-06-12 IN8bio, Inc. Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051151A1 (en) * 1999-01-28 2001-12-13 Lamb Lawrence S. In vitro activated gamma delta lymphocytes
US20050118142A1 (en) * 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20110044959A1 (en) * 2008-03-15 2011-02-24 Trivedi H L Novel composition of stem cells for transplantation tolerance
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
CN103635573A (zh) * 2011-05-19 2014-03-12 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
CN103834615A (zh) * 2014-03-27 2014-06-04 叶永清 一种适用于培养γδT细胞的无血清培养基
US20140308250A1 (en) * 2011-03-17 2014-10-16 Miltenyi Biotec Gmbh Cell preparations depleted of tcr alpha/beta
US20140328804A1 (en) * 2011-06-09 2014-11-06 University Of Florida Research Foundation, Inc. Method for Treating or Preventing Graft Versus Host Disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699235B1 (en) * 1993-05-17 2007-05-09 Yeda Research And Development Company, Ltd. Animal model for hepatitis virus infection
EP1147186A4 (en) * 1999-01-28 2002-05-15 Palmetto Health Alliance D B A In vitro activated gamma delta lymphocytes
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2593098A4 (en) * 2010-07-16 2014-02-05 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
US9556271B2 (en) * 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
JP2015504047A (ja) * 2011-12-22 2015-02-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期の生着のための併用療法
EP3060059A4 (en) * 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
CN108025023A (zh) * 2015-08-25 2018-05-11 Uab研究基金会 用于干细胞移植的方法
ES2983739T3 (es) * 2016-08-18 2024-10-24 Uab Res Found Composiciones y procedimientos para la inmunoterapia del cáncer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051151A1 (en) * 1999-01-28 2001-12-13 Lamb Lawrence S. In vitro activated gamma delta lymphocytes
US20050118142A1 (en) * 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
US20110044959A1 (en) * 2008-03-15 2011-02-24 Trivedi H L Novel composition of stem cells for transplantation tolerance
US20140308250A1 (en) * 2011-03-17 2014-10-16 Miltenyi Biotec Gmbh Cell preparations depleted of tcr alpha/beta
CN103635573A (zh) * 2011-05-19 2014-03-12 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
US20140328804A1 (en) * 2011-06-09 2014-11-06 University Of Florida Research Foundation, Inc. Method for Treating or Preventing Graft Versus Host Disease
CN103834615A (zh) * 2014-03-27 2014-06-04 叶永清 一种适用于培养γδT细胞的无血清培养基

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
E. RADESTAD ET AL.: "Alpha/Beta T-Cell Depleted Grafts as an Immunological Booster to Treat Graft Failure after Hematopoietic Stem Cell Transplantation with HLA-Matched Related and Unrelated Donors", 《JOURNAL OF IMMUNOLOGY RESEARCH》 *
IRMA AIROLDI ET AL.: "γδT-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-ab1/CD191 lymphocytes", 《BLOOD》 *
M SMETAK ET AL.: "Clinical-scale single-step CD4 + and CD8+ cell depletion for donor innate lymphocyte infusion (DILI)", 《BONE MARROW TRANSPLANTATION》 *
S CHALEFF ET AL.: "A large-scale method for the selective depletion of αβ T lymphocytes from PBSC for allogeneic transplantation", 《CYTOTHERAPY》 *
吴秀丽等: "γδ细胞在造血干细胞移植中的应用前景", 《国际输血及血液学杂志》 *
黄河: "同种异基因单倍体相合的造血干细胞移植新进展", 《实用肿瘤杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137752A (zh) * 2015-08-25 2022-10-04 Uab研究基金会 用于干细胞移植的方法

Also Published As

Publication number Publication date
EP4458953A3 (en) 2025-01-22
IL257678B1 (en) 2023-12-01
JP7105188B2 (ja) 2022-07-22
CA2996522A1 (en) 2017-03-02
ES2984387T3 (es) 2024-10-29
EP4458953A2 (en) 2024-11-06
AU2016312610B2 (en) 2023-02-16
EP3340997B1 (en) 2024-02-14
IL257678A (en) 2018-04-30
EP3340997A4 (en) 2019-03-06
KR20180041229A (ko) 2018-04-23
JP2018525417A (ja) 2018-09-06
EP3340997A1 (en) 2018-07-04
JP2022133453A (ja) 2022-09-13
AU2016312610A1 (en) 2018-04-12
NZ740901A (en) 2024-12-20
KR20250048489A (ko) 2025-04-08
US20190183930A1 (en) 2019-06-20
WO2017035375A1 (en) 2017-03-02
IL257678B2 (en) 2024-04-01
CN115137752A (zh) 2022-10-04
US20220265720A1 (en) 2022-08-25
AU2023202946A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US20220265720A1 (en) Methods for stem cell transplantation
Morris et al. NKT cell–dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
Serody et al. Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation
Lundqvist et al. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions
EP3180011B1 (en) Immunotherapy for the treatment of cancer
CN103068973A (zh) 表达Th1特性和溶细胞性质的细胞
Locatelli et al. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation
Yarkoni et al. IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy
MacDonald et al. Donor pretreatment with progenipoietin-1 is superior to G-CSF in preventing graft-versus-host disease after allogeneic stem cell transplantation
HK1257636B (en) Methods for stem cell transplantation
HK1257636A1 (en) Methods for stem cell transplantation
JP5807769B2 (ja) 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用
Fassas et al. Separating graft-versus-tumor from graft-versus-host reactions
US20100129329A1 (en) METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION
KR20130023797A (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
Herberman Therapy of cancer with interleukin-2-activated natural killer cells
Stankevich et al. Experience of clinical mesenchymal stem cells (MSCs) usage for prophylaxis and GVHD treatment in patients undergoing allo-HSCT
Kolb et al. W Zhao, JJ Li, DY Cao et al.,“Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis" World Journal of Gastroenterology, vol. 18, no. 10, pp. 1048–1058

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180511